Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Relmada Therapeutics Inc
RLMD | US
7.06
USD-0.08
-1.12%
RLMD | US
About Relmada Therapeutics Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
22/04/2026
Close
7.06
Open
7.22
High
7.37
Low
7.02
Relmada Therapeutics Inc. a clinical-stage biotechnology company focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone dextromethadone and REL-1017) a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables Florida.
View LessRLMD | US
Risk
67.8
Sharpe
12.92
Luna's Score
52/100
Recommendation
Hold
Luna says (RLMD | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
66.9%1 month
67.8%3 months
141.6%6 months
123.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.71
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
0.54
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-161.25M
MarketCap
213.03M
MarketCap(USD)
213.03M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-100.41
Short ratio
3.86
Short perc.
4.22
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.13
Range1M
2.26
Range3M
4.72
Volumes: Market Activity
Rel. volume
0.82
Price X volume
8.50M
